DiaSys Announces New U.S. Patent and Product Launch Worldwide.Health/Medical Writers WATERBURY, Conn.--(BW HealthWire)--Nov. 8, 2001 DiaSys Corporation (AMEX AMEX See: American Stock Exchange :DYX DYX Dyslexia ), a global healthcare products company, today announced the worldwide marketing launch of its new, disposable product Disposable products are items that are not intended by the manufacturer to be reused more than once or a few times as compared to more permanent serviceable and reusable items. Some products that have disposable versions are:
The Parasep product line is only one of several products acquired by DiaSys as a result of the Company's acquisition (September, 2000) of Intersep, Ltd. (private), a UK-based manufacturer of consumable laboratory products, supplies and test kits. John R. Cordeiro, DiaSys Director of Marketing Services said, "We have just received a U.S. patent for our Parasep technology from the United States Office of Patents and Trademarks. "We believe that our Parasep products, in combination with our FE-2 Series Workstations, offer the most complete and cost-effective laboratory system available for the automated analysis of intestinal parasites." Robert M. Felcher, DiaSys Director of Sales & Service stated, "The unique and superior filtering qualities of our Parasep products enable hospital and clinical reference laboratory personnel to readily, and more safely, filter ova ova (o´vah) plural of ovum. Ova Eggs. Mentioned in: Stool O & P Test ova plural of ovum. and parasites from fecal specimens for analysis. The Company is marketing its Parasep products as a "stand alone" product line, and also as part of a complete system with its FE-2 Series Automated Ova & Parasite Analysis Workstations." DiaSys products are marketed and sold in the United States, Europe and China through the Company's direct sales force and a network of authorized distributors. The Company also markets its product through strategic business relationships, such as with the Diagnostic Division of Bayer Corporation, the U.S. subsidiary of the chemical and healthcare giant, Bayer AG (Frankfurt: 575200.F) and Allegiance Corporation, a Cardinal Health company (NYSE NYSE See: New York Stock Exchange : CAH CAH congenital adrenal hyperplasia. CAH Congenital adrenal hyperplasia, see there ). DiaSys Corporation designs, develops, manufactures and distributes medical laboratory instrumentation, consumables, reagents and test kits with applications in urinalysis, microbiology, electrophoresis, immunology and cytology cytology (sītŏl`əjē), in biology, the study of the structure of all normal and abnormal components of cells and the changes, movements, and transformations of such components. . DiaSys and Parasep are registered trademarks of DiaSys Corporation. The foregoing press release includes "forward looking statements" within the meaning of, and made pursuant to, the safe harbor Safe Harbor 1. A legal provision to reduce or eliminate liability as long as good faith is demonstrated. 2. A form of shark repellent implemented by a target company acquiring a business that is so poorly regulated that the target itself is less attractive. provisions of the Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and of 1995. Such forward looking statements involve known and unknown risks, uncertainties, and other factors which may cause the actual results, performance or achievements of the Company or events, or timing of events, relating to the Company to materially differ from those expressed or implied by such forward looking statements. DiaSys refers interested parties to its most recent Annual Report on form 10-KSB and other SEC filings for a complete description of, and discussions about, the Company. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion